Abstract
Animal models of neurodegenerative diseases have helped us to better understand the pathogenesis of neurodegenerative diseases. However, recent failure to translate pre-clinical model studies to the clinic urges us to develop more rigorous and faithful animal models in neurodegenerative diseases. As genetic manipulation of rats becomes much more accessible due to availability of CRISPR-Cas9 and other genomic editing toolboxes, rats have been emerging as a new model system for neurodegenerative diseases. Even though mouse models have been dominant over the last decades, rats may provide advantages over mice. Rats are more genetically and physiologically closer to humans than to mice. Also, certain rat models can represent deposition of tau, which is one of the key pathological features of Alzheimer’s diseases and tauopathies. However, there is an unmet need for standardized, rigorous testing in rat models. We adopted two commonly used biochemical and immunofluorescence methods from mice and human postmortem brains to measure tau aggregation. Due to the intrinsic differences between mice and rats, e.g., size of rat brains, certain equipment is required for rat models to study tau pathologies. Along with specific tools, here we describe the detailed methods for rat models of neurodegenerative diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wong W (2020) Economic burden of Alzheimer disease and managed care considerations. Am J Manag Care 26:S177–S183
Yang W, Hamilton JL, Kopil C et al (2020) Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis 6:15
Sheppard O, Coleman M (2020) Alzheimer’s disease: etiology, neuropathology and pathogenesis. In: Huang X (ed) Alzheimer’s disease: drug discovery, Brisbane (AU)
Dawson TM, Golde TE, Lagier-Tourenne C (2018) Animal models of neurodegenerative diseases. Nat Neurosci 21:1370–1379
Hsiao KK, Borchelt DR, Olson K et al (1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15:1203–1218
Quon D, Wang Y, Catalano R et al (1991) Formation of beta-amyloid protein deposits in brains of transgenic mice. Nature 352:239–241
Games D, Adams D, Alessandrini R et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523–527
Holcomb L, Gordon MN, Mcgowan E et al (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97–100
Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a rat race? Dis Model Mech 9:1079–1087
Gibbs RA, Weinstock GM, Metzker ML et al (2004) Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428:493–521
Jacob HJ, Kwitek AE (2002) Rat genetics: attaching physiology and pharmacology to the genome. Nat Rev Genet 3:33–42
Francis C, Natarajan S, Lee MT et al (2014) Divergence of RNA localization between rat and mouse neurons reveals the potential for rapid brain evolution. BMC Genomics 15:883
Do Carmo S, Cuello AC (2013) Modeling Alzheimer’s disease in transgenic rats. Mol Neurodegener 8:37
Hanes J, Zilka N, Bartkova M et al (2009) Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies. J Neurochem 108:1167–1176
Cohen RM, Rezai-Zadeh K, Weitz TM et al (2013) A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci 33:6245–6256
Hyman B (2023) All the tau we cannot see. Annu Rev Med 74:503–514
Lee Y, Miller MR, Fernandez MA et al (2021) Early lysosome defects precede neurodegeneration with amyloid-beta and tau aggregation in NHE6-null rat brain. Brain 145:3187
Agca C, Fritz JJ, Walker LC et al (2008) Development of transgenic rats producing human beta-amyloid precursor protein as a model for Alzheimer’s disease: transgene and endogenous APP genes are regulated tissue-specifically. BMC Neurosci 9:28
Pang K, Jiang R, Zhang W et al (2022) An App knock-in rat model for Alzheimer’s disease exhibiting Abeta and tau pathologies, neuronal death and cognitive impairments. Cell Res 32:157–175
Leon WC, Canneva F, Partridge V et al (2010) A novel transgenic rat model with a full Alzheimer’s-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 20:113–126
Acknowledgments
This work was supported by NIH/NIA grant (F32AG066372), NIH/NIA grant (K99AG076868), NIH/NINDS/NIA grant R01NS113141, and NIH/NINDS R01NS121618.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Lee, Y., Morrow, E.M. (2024). Quantitative Measurement of Tau Aggregation in Genetically Modified Rats with Neurodegeneration. In: Ray, S.K. (eds) Neuroprotection. Methods in Molecular Biology, vol 2761. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3662-6_21
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3662-6_21
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3661-9
Online ISBN: 978-1-0716-3662-6
eBook Packages: Springer Protocols